Company Encyclopedia
View More
name
GRI Bio
GRI.US
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc.
1.936 T
GRI.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    12 Health Care Stocks Moving In Friday's After-Market Session

    During Friday's after-market session, several health care stocks experienced price changes. Gainers included Milestone Scientific, Streamex, GRI Bio, Intensity Therapeutics, Can Fite Biofarma, and SciSparc, with increases ranging from 3.86% to 4.7%. Losers included BioAtla, Nexalin Technology, Greenwich LifeSciences, Aspire Biopharma Holdings, Anebulo Pharmaceuticals, and Rein Therapeutics, with declines ranging from 3.4% to 6.2%.

    benzinga_article·
    US
    ASBP
    +11.34%
    US
    GRI
    -14.55%
    US
    RNTX
    -6.06%
    benzinga_article·
    US
    ASBP
    +11.34%
    US
    GRI
    -14.55%
    US
    RNTX
    -6.06%

    GRI Bio Inc. Announces Date for Upcoming Special Stockholders Meeting

    GRI Bio, Inc. will hold a virtual special stockholders meeting on January 15, 2026, via live audio webcast. This announcement was originally published by GRI Bio Inc. via EDGAR on December 19, 2025.

    Reuters·
    US
    GRI
    -14.55%
    Reuters·
    US
    GRI
    -14.55%

    GRI Bio Launches $6.7 Million Public Offering

    GRI Bio, Inc. launched a public offering on December 11, 2025, aiming to raise $6.7 million through common stock, pre-funded warrants, and Series F warrants. The proceeds will support working capital, product development, and general corporate purposes, funding operations into Q4 2026. The offering closes on December 12, 2025, with institutional investor agreements and stock issuance restrictions. Analysts rate GRI stock as a Buy with a $10 target, but caution due to weak financials and negative profitability.

    Tip Ranks·
    US
    GRI
    -14.55%
    Tip Ranks·
    US
    GRI
    -14.55%

    GRI Bio reports positive phase 2a data in idiopathic pulmonary fibrosis

    GRI Bio announced positive topline results from its phase 2a clinical trial of GRI-0621 in idiopathic pulmonary fibrosis (IPF). The study met primary and secondary endpoints, showing the drug was well tolerated and demonstrated disease-modifying activity. No severe adverse events were reported. Improvements in forced vital capacity and biomarkers suggested fibrosis resolution and lung repair. CEO Marc Hertz highlighted the drug's potential to impact core drivers of IPF.

    PharmaTimes·
    US
    GRI
    -14.55%
    PharmaTimes·
    US
    GRI
    -14.55%

    GRI Bio shares are trading higher after the company announced topline data from the Phase 2a GRI-0621-IPF-02 clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis met its primary and secondary endpoints.

    benzinga_article·
    US
    GRI
    -14.55%
    benzinga_article·
    US
    GRI
    -14.55%
    © 2025 Longbridge｜Disclaimer